
|Videos|July 13, 2022
Available Second-Line Treatments for Transplant-Ineligible R/R DLBCL
Author(s)Grzegorz S. Nowakowski, MD
Dr Grzegorz S. Nowakowski reviews the currently available second-line treatment options for transplant-ineligible R/R DLBCL.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
3
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
4
FDA Oncology Update January 2026: New Horizons in Precision Medicine
5



















